Rates of incident clinical vertebral fracture, incident nonvertebral fracture, hip fracture, and clinical fractures decreased 6 months after initiation of teriparatide.
Genetic testing may identify individuals with an increased risk for osteoporosis and bone fracture.
Only one-third of Canadian patients received hip fracture repair surgery within the desired 24 hours.
A corrected HbA1c factor may improve the ability to predict the risk for fracture by the FRAX algorithm in T2D.
Researchers observed a reduction in subsequent nonvertebral fracture rates in patients who initiated osteoporosis treatment.
Investigators examined the effect of consuming a Mediterranean-style diet for 1 year on inflammatory response and bone health in the elderly.
The risk for bone fractures was not increased in patients with type 2 diabetes using empagliflozin compared with placebo or glimepiride.
The Biologics License Application has been resubmitted for Evenity, an investigational treatment for osteoporosis in postmenopausal women at high risk for fracture.
Romosozumab increased spine and hip bone mineral density after 12 months of treatment.
Pain resulting from osteoporotic fractures should be treated with a multimodal approach that includes pharmacological and nonpharmacological strategies.
Postmenopausal women have little awareness of osteoporotic fracture risk and poor understanding that a fragility fracture may be indicative of osteoporosis and that it increases future fracture risk.
Screening is recommended for women aged ≥65 years and younger women who have been through menopause and are at increased risk for osteoporosis.
Use of alendronate in individuals who experience a hip fracture is associated with a reduced risk for cardiovascular mortality, myocardial infarction, and stroke.
High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
Researchers assessed the incidence of Cutibacterium avidum infection in patients following primary hip arthroplasty.
Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.
Negative effects of 2-hour glucose was pronounced at the cortical-bone-dominant sites in women.
The FDA has approved use of Prolia for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.
Investigators sought to determine whether both restrictive and purging types of anorexia nervosa effect bone metabolism.
An osteoporosis treatment may have a positive effect on human hair follicles from those undergoing hair transplantation surgery.
The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).
Findings do not support a role for subclinical thyroid dysfunction as a biomarker for bone-related outcomes in older men.
Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.
A high stress fracture rate in oligo-amenorrheic athletes, who have whole body, less head and hip, areal bone mineral density (BMD) measures comparable to those of control patients, indicates that BMD in these women may need to be even higher to avoid fractures.
Researchers found that estimation of hip fracture risk without accounting for death as a competing event results in an overestimation of fracture risk.
Sciatic nerve block may represent an effective complement to femoral nerve block for total knee arthroplasty.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.
Anti-osteoporotic medications (mainly bisphosphonates) seem to equally prevent bone loss, especially in the lumbar spine, in patients with diabetes compared with patients without diabetes.
Rheumatology Advisor Articles
- Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks
- Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in Axial Spondyloarthritis
- Knee Load Associated With Increased Walking Pain in Osteoarthritis
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- CVD Prevention Measures Inadequate in Patients With Inflammatory Joint Diseases
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- Exploring the Clinical Implications of Cannabinoid Use in Rheumatoid Arthritis
- Diagnosing Lyme Disease in Children With Neuropsychiatric Illness
- Predicting Primary Nonresponse to Methotrexate in Rheumatoid Arthritis
- Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA
- Sulfasalazine Reduces Pneumocystis Pneumonia Risk in Rheumatoid Arthritis
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Response to Certolizumab Pegol at 12 Weeks Predicts Long-Term RA Outcomes
- Performance Phenotypes of Lumbar Spinal Stenosis and OA With Accelerometry Data
- Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions